🇺🇸 FDA
Patent

US 10662416

Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome

granted A61KA61K38/00A61K38/43

Quick answer

US patent 10662416 (Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome) held by Precision BioSciences, Inc. expires Mon May 21 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Precision BioSciences, Inc.
Grant date
Tue May 26 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 21 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K38/00, A61K38/43, A61K9/51, A61P